ProQR Therapeutics (PRQR) Cash from Operations (2013 - 2026)

ProQR Therapeutics has reported Cash from Operations for 14 years, with the latest figure at 13422598.88 in Q1 2026.

• Quarterly Cash from Operations rose 22.08% year-over-year to 13422598.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58889393.65 (down 34.78% YoY) and the FY2025 annual result came in at 63541643.34, down 52.19% from the prior year.
• Cash from Operations improved to 13422598.88 in Q1 2026 per PRQR's latest filing, from 17638751.38 in the prior quarter.
• Over five years, Cash from Operations peaked at 47812011.35 in Q1 2023 and troughed at 22970886.08 in Q1 2022.
• A 5-year average of 9923371.23 and a median of 13524654.35 in 2025 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 466.29% in 2022, then surged 308.14% in 2023.
• Over 5 years, Cash from Operations stood at 18194071.27 in 2022, then jumped by 78.88% to 3843257.35 in 2023, then slumped by 234.38% to 12850928.28 in 2024, then plunged by 37.26% to 17638751.38 in 2025, then gained by 23.9% to 13422598.88 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 13422598.88, 17638751.38, and 14303389.04 for Q1 2026, Q4 2025, and Q3 2025 respectively.